| 证券代码 | PTX.O |
| 证券名称 | Pernix Therapeutics Holdings Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2013-01-28 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Pernix Therapeutics Holdings, Inc. |
| 注册地址 | 美国马里兰州 |
| 办公地址 | 10 North Park Place, Suite 201, Morristown, New Jersey, USA |
| 成立日期 | 1996-11 |
| 董事会主席 | John A. Sedor |
| 公司属地 | United States 美国 |
| 公司网址 | www.pernixtx.com |
| 电话 | +1 (800) 793-2145 |
| 传真 | +1 (862) 260-8752 |
| 公司简介 | Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs, primarily for the U.S. market. The Company is currently focused on the therapeutic areas of pain and neurology, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceuticals, Inc. |